Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges

Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD

(2019) Mary E. Rinella et al.   JOURNAL OF HEPATOLOGY

Resolving the fibrotic niche of human liver cirrhosis at single-cell level

(2019) P. Ramachandran et al.   NATURE

Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis

(2018) Frank Tacke   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis

(2018) Oliver Krenkel et al.   HEPATOLOGY

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

(2018) Scott L. Friedman et al.   HEPATOLOGY

Effects of treatment with Maraviroc a CCR5 inhibitor on a human hepatic stellate cell line

(2018) Nicola Coppola et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Pharmacological inhibition of CCR2/5 signaling prevents and reverses alcohol-induced liver damage, steatosis and inflammation in mice

(2018) Aditya Ambade et al.   HEPATOLOGY

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis

(2017) Parambir S. Dulai et al.   HEPATOLOGY

Functional role of CCL5/RANTES for HCC progression during chronic liver disease

(2017) Antje Mohs et al.   JOURNAL OF HEPATOLOGY

Mechanisms of hepatic stellate cell activation

(2017) Takuma Tsuchida et al.   Nature Reviews Gastroenterology & Hepatology

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

(2017) Zobair Younossi et al.   Nature Reviews Gastroenterology & Hepatology

Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment

(2016) E Lefebvre et al.   CTS-Clinical and Translational Science

The role of macrophages in obesity-driven chronic liver disease

(2016) Lindsey Devisscher et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Blocking the CCL2–CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model

(2016) Kun-Yu Teng et al.   MOLECULAR CANCER THERAPEUTICS

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis

(2016) Eric Lefebvre et al.   PLoS One

Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma

(2015) Xiaoguang Li et al.   GUT

Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C+macrophage infiltration in mice

(2014) Christer Baeck et al.   HEPATOLOGY

CCL5 secreted from bone marrow stromal cells stimulates the migration and invasion of Huh7 hepatocellular carcinoma cells via the PI3K-Akt pathway

(2014) HUILI BAI et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Inflammation-induced hepatocellular carcinoma is dependent on CCR5 in mice

(2013) Neta Barashi et al.   HEPATOLOGY

Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury

(2011) Christer Baeck et al.   GUT

Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice

(2010) Marie-Luise Berres et al.   JOURNAL OF CLINICAL INVESTIGATION